The use of tPA is limited by its narrow therapeutic window of 3 to 4.5h post-onset of ischemic stroke, and the administration of tPA beyond its therapeutic window has been linked to increased risks of aggravated BBB disruption and HT induction. Here, PLAT is linked to ischemic stroke.